



## RESprotect History at a Glance

**2000** SciClone developed the first RP101 based clinical trial for the treatment of metastatic colorectal cancer. North-American rights of the company Excite Drugs RP101 a second line agent study, Los Angeles

**2007** SciClone transferred the North-American rights of RP101 to Kwang Dong Pharmaceuticals/Seoul, South Korea

**2008** SciClone transferred the North-American rights of RP101 to Kwang Dong Pharmaceuticals/Seoul, South Korea

**2009-2010** SciClone transferred the RP101, RP105 and RP106 North American rights to RESprotect

is currently aiming for strategic partnerships to develop and market RP101 and its next generation product candidates on a worldwide basis.